Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell LeukemiaDai Chihara, Robert J. Kreitman, Evgeny Arons et al.|Journal of Clinical Oncology|2020Cited by 104
COVID-19 in patients with classic and variant hairy cell leukemiaRobert J. Kreitman, Evgeny Arons, Theresa Yu et al.|Blood Advances|2023Cited by 5
Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell TherapyRobert J. Kreitman, Nirali N. Shah, Brett Schroeder et al.|JCO Precision Oncology|2025Cited by 2
Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab PasudotoxR. J. Kreitman, Ira Pastan, Constance M. Yuan et al.|Blood|2024Cited by 1
A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell LeukemiaRobert J. Kreitman, Constance M. Yuan, Hao‐Wei Wang et al.|Blood|2024Cited by 0